Haploidentical Hematopoietic Stem Cell Transplantation with Co-Infusion of Mesenchymal Stromal Cells for Acquired Severe Aplastic Anemia: A Report of 127 Cases.
10.19746/j.cnki.issn.1009-2137.2022.04.041
- Author:
Dong-Mei HAN
1
;
Li DING
1
;
Xiao-Li ZHENG
1
;
Hong-Min YAN
1
;
Mei XUE
1
;
Jing LIU
1
;
Ling ZHU
1
;
Sheng LI
1
;
Heng-Xiang WANG
2
Author Information
1. Department of Hematology, Air Force Medical Center, Beijing 100142, China.
2. Department of Hematology, Air Force Medical Center, Beijing 100142, China,E-mail: wanghengxiang123@aliyun.com.
- Publication Type:Journal Article
- Keywords:
haplo-identical hematopoietic stem cell transplantation;
mesenchymal stromal cell;
severe aplastic anemia
- MeSH:
Adult;
Anemia, Aplastic/therapy*;
Child;
Female;
Graft vs Host Disease;
Hematopoietic Stem Cell Transplantation/adverse effects*;
Humans;
Male;
Mesenchymal Stem Cells;
Retrospective Studies;
Transplantation Conditioning/adverse effects*;
Treatment Outcome
- From:
Journal of Experimental Hematology
2022;30(4):1230-1237
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze the prognostic factors of haplo-HSCT combined with MSC in the treatment of SAA.
METHODS:127 SAA patients who had undergone haplo-HSCT with co-infusion of MSC in our center from January 2014 to August 2019 were analyzed retrospectively. Median age was 11 (1-37) years, and median follow-up time was 39.8 (1-74) months.
RESULTS:The median time for neutrophil and platelet engraftment was 14 d and 18 d respectively. The cumulative incidences of grade III-IV aGVHD was 4.4%±1.9% at day +100. The 2-year cumulative incidence of extensive cGVHD was 8.3%± 2.7%. The estimated 3-year OS was 86.1%±3.1%. Univariate analysis showed that high-dose CD34+ cells (>6.69×106/kg) could promote the engraftment of neutrophil (97.9%±0.05% vs 88.6%±0.13% at day +21, P=0.0006) and platelet (81.2%±0.33% vs 70.8%±0.26% at day +28, P=0.002) and did not increase the incidence of aGVHD (10.4%±0.1% vs 18.9%±0.1% at day +100, P=0.18). More nucleated cells (>12.78×108/kg) caused a lower incidence of grade II-IV aGVHD (8.6%±0.13% vs 21.7%±0.25% at day+100, P=0.04) and a higher incidence of 3-year OS (91.3%±3.2% vs 78.1%±6.5%, P=0.03) than less nucleated cells (≤12.78×108/kg). Younger patients (age≤12 y) had faster neutrophil engraftment (94.9%±0.06% vs 87.5%±0.24% at day+21, P=0.02), higher 3-year OS (93.6%±2.8% vs 75.9%±6.4%, P=0.006) and higher 3-year FFS (93.6%±2.8% vs 68.3%±7.1%, P=0.000) than older patients (age>12 y). The shorter the time from diagnosis to HSCT (≤29.5 months), the higher the 3-year FFS of patients (88.8%±3.5% vs 74.2%±7.2%, P=0.028). Male patients with female donors had higher cumulative incidence of extensive cGVHD than others (20.0%±0.8% vs 4.6%±0.1%, P=0.01).
CONCLUSION:In the haplo-HSCT of SAA, the prognosis of children patients is better than that of adults patients. More CD34+ cells and nucleated cells can promote engraftment, reduce the incidence of aGVHD and improve OS. HSCT should be performed as early as possible, and the occurrence of cGVHD should be reduced in male patients by avoiding female donors.
